Strategic Performance Drivers

Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here.

• Performance was driven by a 'compounding engine' where 24% growth in new surgeon adoption and 20% procedural volume growth fueled a 15% revenue increase.

• Management attributes the 17% surgical revenue growth to a shift from selling individual 'widgets' to architecting entire procedures, particularly in lateral surgery.

• The EOS imaging platform serves as a critical 'hunting license,' providing access to prestigious academic institutions and fellowship programs that were previously inaccessible.

• Profitability expansion was achieved through disciplined resource allocation and a 260-basis-point improvement in gross margins, driven by inventory efficiency and supply chain volume leverage.

• The company is successfully replicating its clinical distinction model in high-value international markets like Japan and Australia, which is beginning to contribute meaningfully to the top line.

• Management highlighted that 32% revenue lift per surgeon is observed within six months of EOS Insight adoption, validating the informatics platform as a driver of implant pull-through.

Outlook and Strategic Initiatives

• Full-year surgical revenue guidance remains at $805 million, implying an acceleration to 18% growth in the second half of 2026.

• Adjusted EBITDA guidance was raised to $140 million (16% margin) based on sustained gross margin improvements and operating discipline.

• Management expects high-teens surgical case volume growth in the second half, supported by front-loaded investments of $66 million in inventory and instrument sets.

• Free cash flow is projected to reach $4 million to $6 million in Q3, stepping up significantly in Q4 as capital expenditure on instrument sets moderates.

• The long-term strategy focuses on converting the EOS data moat into predictive analytics for surgical planning, aiming for $1 billion in revenue by 2027.

Operational Context and Risk Factors

• Revenue per case declined 2.7% year-over-year, primarily due to stabilized but lower-than-expected biologics attachment and international mix headwinds.

• A new capital structure with JPMorgan and TD Cowen consolidated legacy facilities, extending maturities to 2031 and reducing annual interest expense by over $6 million.

• Biologics attachment remains a focused area for execution; management plans to address this through sales discipline and the future launch of a BMP product via the Theradaptive partnership.

• Management noted that EOS installations can be 'bumpy' quarter-to-quarter due to facility space requirements and complex installation dynamics rather than lack of demand.